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Shear stress triggers von Willebrand factor (VWF)
binding to platelet glycoprotein Ib and subsequent
integrin IIb3-dependent platelet aggregation. Con-
comitantly, nucleotides are released from platelet-
dense granules, and ADP is known to contribute to
shear-induced platelet aggregation (SIPA). We found
that the impaired SIPA of platelets from a Hermansky-
Pudlak patient lacking dense granules was restored by
exogenous L-,-methylene ATP, a stable P2X1 agonist,
as well as by ADP, confirming that in addition to ADP
(via P2Y1 and P2Y12), ATP (via P2X1) also contributes
to SIPA. Likewise, SIPA of apyrase-treated platelets
was restored upon P2X1 activation with L-,-methyl-
ene ATP, which promoted granule centralization
within platelets and stimulated P-selectin expression,
which is a marker of -granule release. In addition,
during SIPA, platelet degranulation required both ex-
tracellular Ca2 and VWF-glycoprotein Ib interac-
tions without involving IIb3. Neither platelet release
nor SIPA was affected by protein kinase C inactiva-
tion, even though protein kinase C blockade inhibits
platelet responses to collagen and thrombin in stirring
conditions. In contrast, inhibiting myosin light chain
(MLC) kinase with ML-7 reduced platelet release and
SIPA by 30%. Accordingly, the potentiating effect of
P2X1 stimulation on the aggregation of apyrase-
treated platelets coincided with intensified phospho-
rylation of MLC and was abrogated by ML-7. SIPA-
induced MLC phosphorylation occurred exclusively
through released nucleotides and selective antago-
nism of P2X1 with MRS2159-reduced SIPA, ATP re-
lease, and potently inhibited MLC phosphorylation.
We conclude that the P2X1 ion channel induces MLC-
mediated cytoskeletal rearrangements, thus contrib-
uting to SIPA and degranulation during VWF-trig-
gered platelet activation.
Blood platelets are constantly subjected to hemodynamic
forces imposed by the blood flow, including fluid shear stress.
High shear stress is generated at sites of arterial injury where
laminar blood flow is forced through a stenosis (1, 2). Shear
stress-triggered platelet activation and subsequent aggrega-
tion, termed SIPA1 (3), may thus contribute to the pathogenesis
of vascular diseases. In addition, platelets from patients with
acute myocardial infarction (4) or cerebral ischemia (5) display
enhanced SIPA in vitro.
High shear stress is required for the interaction between von
Willebrand factor (VWF) and platelet glycoprotein Ib (GPIb)
(for review, see Ref. 6), but the effects of shear forces on GPIb
signaling are only just beginning to be defined. Downstream
effectors that have been implicated in the VWF-dependent
activation of IIb3 include phosphatidylinositol 3-kinase
(PI3K) (7), protein kinase C (PKC) (8), Syk, and Src, as well as
co-associated immunoreceptor tyrosine-activated motif-con-
taining transmembrane proteins and adaptor proteins (2). A
recent study of platelet adhesion to dimeric VWF A1 domain,
which recognizes only GPIb, showed that GPIb itself can
signal to activate IIb3 through sequential actions of Src ki-
nases, Ca2 oscillations, and PI3K/PKC (9). It has also been
proposed that GPIb signals directly as a consequence of its
association with structural cytoskeletal proteins (10), among
which GPIb-bound filamin A, filamentous actin cross-linked
by -actinin, vinculin, and talin would directly link the cyto-
plasmic domain of GPIb with the 3 tail of IIb3 (11).
Studies examining SIPA have suggested that VWF primarily
stimulates platelet activation through an indirect pathway
linked to ADP release (12, 13). These studies have also shown
that platelet activation initiated by VWF-GPIb interaction
requires a transmembrane Ca2 influx independent of released
ADP and VWF binding to IIb3 (14, 15), which promotes dense
granule secretion of ADP and activates integrin IIb3 through
engagement of the P2 receptors for ADP. A role for the platelet
ADP receptors P2Y1 and P2Y12 (reviewed in Ref. 16) in SIPA
has subsequently been confirmed (17, 18). Rese´ndiz et al. (19)
recently reported that the selective P2Y12 antagonist AR-
C69931MX inhibits the shear-induced aggregation of washed
platelets and showed that P2Y12 mediates shear-induced PI3K
activation, a process coupled to phosphorylation of PI3K-asso-
ciated Syk tyrosine kinase.
In blood vessels, shear stress causes the release of high levels
of nucleotides, including ATP and ADP, into the extracellular
environment; these nucleotides mainly originate from endothe-
lial cells (20) and platelet-dense granules (21). Although the
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shear-induced ATP release from endothelial cells probably in-
volves vesicular exocytosis (22), the molecular mechanisms of
such a release are largely unknown. In platelets, the time
course of this ATP release appeared to parallel the association
of myosin with the actin cytoskeleton, suggesting that these
two processes are related (21). In addition, Ca2 influx-depend-
ent phosphorylation of myosin light chain, preceding the myo-
sin-actin interactions, has been proposed to be an initial step
during SIPA (21).
ATP is the physiological agonist at P2X1, but its role in
platelet activation is only starting to be unraveled. In the
aggregometer, the selective P2X1 agonists ,-meATP and
L-,-meATP evoke a transient Ca2 influx accompanied by
rapid and reversible platelet shape change and myosin light
chain (MLC) phosphorylation, provided that measures are
taken to avoid desensitization of P2X1 by ATP spontaneously
released during platelet preparation (23–25). Recent studies,
using P2X1 knock-out mice (26) or transgenic mice overexpress-
ing this ion channel selectively in the megakaryocytic cell lin-
eage (27), have reported a prominent role for P2X1 in platelet
aggregation and thrombus formation in shear stress condi-
tions. Notably, P2X1 overexpressing platelets displayed potent
SIPA in conditions where wild-type platelets hardly aggregated
(27). In the present study, we have investigated the role of the
P2X1-mediated Ca
2 influx and the associated downstream
signaling pathways in VWF-dependent shear-induced granule
release and aggregation of washed human platelets.
EXPERIMENTAL PROCEDURES
Materials—ADP, L-,-meATP, the P2X1 antagonist MRS2159, the
P2Y1 antagonist MRS2179, and the ectonucleotidase apyrase (grade I)
were purchased from Sigma. AR-C69931MX was a gift from AstraZeneca
R&D, Charnwood, UK. The P2X1 antagonist MRS2159 at the concen-
tration used in this study was verified to selectively inhibit a P2X1-
mediated platelet shape change without affecting platelet shape change
and aggregation induced by ADP. The calmodulin inhibitor W-7, the
MLC kinase inhibitor ML-7, the Rho kinase inhibitor Y-27632, and the
PKC inhibitors GF109203X, Go6976, and Go6983 were purchased from
Calbiochem. Human VWF was purified from plasma cryoprecipitate by
gel filtration on a Sepharose 4B-CL column. Tirofiban (Aggrastat) was
obtained from Merck Sharp and Dohme. The murine-neutralizing anti-
VWF monoclonal antibody AJvW-2 was from Ajinomoto Co., Inc. (Ka-
wasaki, Japan) (28), and the neutralizing monoclonal anti-GPIb anti-
body G19H10 was raised in our laboratory. ADP and L-,-meATP were
purified by high pressure liquid chromatography on an Adsorbosphere
HS C18, 7 m, 250  4.6-mm column (Alltech) as described by Oury et
al. (24).
Preparation of Washed Human Platelets—Washed human platelets
(2.5–3.5  105 platelets/l) were prepared as described previously (29).
Apyrase (0.5 units/ml) was added to the blood sample and platelet
resuspension buffer when indicated. Platelet preparations were free of
red blood cells, as validated via microscopy and blood cell counting
(CellDyn 1300, Abbott, Abbott Park, IL).
Shear-induced Platelet Aggregation, ATP Secretion, and P-selectin
Expression—Shear-induced aggregations of washed human platelets
were performed in an annular ring-shaped viscometer generating lam-
inar flow (Ravenfield viscometer; Heywood, Lancashire, UK) at 37 °C in
the presence of 2 mM CaCl2 and 10 g/ml human soluble VWF unless
otherwise indicated. A shear rate of 9000 s1 was used, which corre-
sponds to a shear stress of 80 dynes/cm2. The threshold shear rate
causing platelet aggregation ranged between 3000 s1 and 5000 s1. At
defined time points, platelet samples were collected and fixed in 1%
paraformaldehyde; the percentage of platelet aggregation was calcu-
lated by comparing single platelet counts before and after shearing.
Shear-induced P-selectin surface translocation on tirofiban-treated
washed platelets was detected by flow cytometry with the phyco-
erythrin-conjugated anti-P-selectin CD62P antibody (BD Biosciences).
For ATP secretion assays, the reactions were stopped with an ice-cold
Hepes buffer (20 mM Hepes, pH 7.4, 150 mM NaCl, 5 mM EDTA). After
immediate centrifugation at 4 °C, ATP was measured in the superna-
tants by the addition of a luciferase/luciferin reagent (Chrono-Lume,
Kordia) in a microplate luminometer LB96V (Berthold Technologies,
Vilvoorde, Belgium). At least five independent experiments were per-
formed on platelets from different individuals. The data are repre-
sented as the mean  S.D. Statistical analysis of the data was done
using nonpaired Student’s t tests.
Immunoblotting Analyses—Platelets (0.3-ml platelet suspensions)
were lysed in SDS sample buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS,
10% glycerol, 50 mM dithiothreitol, 0.1% bromphenol blue). Sample
aliquots were loaded on SDS-PAGE (12.5%) and subjected to Western
blotting. Thr-18/Ser-19 MLC phosphorylation was detected with the
anti-phospho-MLC polyclonal antibody (Santa Cruz Biotechnology,
Santa Cruz, CA) according to the instructions of the manufacturers.
Electron Microscopy—Washed platelets were immediately fixed over-
night at 4 °C in 2.5% (w/v) glutaraldehyde, 0.1 M phosphate buffer, pH
7.2. After centrifugation at 800  g for 10 min, a condensed pellet of
platelets was formed. After fixation in 1% OsO4 (w/v), 0.1 M phosphate
buffer, pH 7.2, and dehydration in a graded series of ethanol, the pellets
were embedded in epoxy resin. Ultrathin sections were cut and stained
with uranyl acetate and lead citrate before examination with a Zeiss
EM 10 electron microscope (Oberkochen, Germany).
RESULTS
VWF-GPIb Interactions and Extracellular Ca2 in SIPA—
When suspensions of washed human platelets were subjected
to uniform high shear stress (80 dynes/cm2  9000 s1 shear
rate) in the presence of soluble human VWF in an annular
ring-shaped viscometer, aggregation rapidly occurred, reaching
a plateau after 3 min (Fig. 1A). In contrast, a shear rate of 1000
s1 did not cause platelet aggregation (Fig. 1A). The inclusion
of the VWF A1 domain-blocking antibody AJvW-2, neutralizing
anti-GPIb antibody G19H10, or the IIb3 antagonist tirofi-
ban (Fig. 1B) confirmed the findings by others (30) that SIPA
requires VWF interactions with GPIb and the activation of
IIb3. We also confirmed that SIPA does not occur in the
absence of added extracellular Ca2 (14, 15) (Fig. 1B).
Platelet aggregation was accompanied by gradually increas-
ing shear stress-dependent ATP release (Fig. 1A). ATP release
was initiated as early as 10 s after exposure to shear stress.
When measured at the maximal aggregation time point, this
release clearly relied on VWF-GPIb signaling, as it was at
least partly inhibited by AJvW-2 and G19H10 (Fig. 1B). Omit-
ting the addition of extracellular Ca2 also reduced the amount
of released ATP, although only partly (Fig. 1B). The combined
absence of VWF and extracellular Ca2 almost abolished plate-
let degranulation (Fig. 1B). In contrast, IIb3 antagonism had
no effect on the degree of platelet degranulation (Fig. 1B).
Therefore, both VWF-GPIb signaling and Ca2 contribute to
platelet release under shear stress, a process that is independ-
ent of IIb3 outside-in signals.
MLC Kinase (but Not PKCs) Controls the SIPA-induced
Platelet Degranulation—Platelet granule release that is induced
by most agonists requires an increase of intracellular Ca2 and
PKC activation (reviewed in Ref. 31). Whether or not PKC plays
a role in SIPA is controversial (8, 32). In our experimental
conditions, the nonselective PKC inhibitor GF109203X, which
blocks both conventional (, I, II, ) and novel (, , , ) PKC
isoforms, failed to inhibit either platelet aggregation or release
produced by shear stress (Fig. 2A), although it prevented such
responses to collagen (2 g/ml) or to the PAR-1-activating pep-
tide TRAP1–6 (1 M) under stirring conditions (Fig. 2B). Simi-
larly, the PKC /-specific inhibitor Go6976 did not affect SIPA
and associated platelet release (Fig. 2A), although shear stress-
independent collagen-induced release and aggregation were
fully blocked (Fig. 2B). In agreement with previous reports that
PKC / isoforms do not play a major role downstream of PAR-1
(33), Go6976 had a minimal inhibitory effect on TRAP1–6-
induced granule release (Fig. 2B). Finally, to determine
whether other PKC isoforms could be involved in platelet re-
lease accompanying SIPA, we used Go6983, which blocks the
platelet-expressed atypical PKC 	 isoform in addition to PKC ,
I, II, , and . This inhibitor had no effect on shear-induced
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platelet release or aggregation, although it diminished TRAP1–
6-induced ATP release by about 50% without affecting platelet
aggregation (Fig. 2B). These results indicate that shear-in-
duced platelet dense granule release and aggregation are de-
pendent on signaling pathways distinct from those activated
downstream of the collagen receptor GPVI or PAR-1. They also
suggest that the known conventional, novel, and atypical PKC
isoforms do not play a major role in platelet degranulation
during SIPA.
In addition to PKC, GPVI-mediated platelet dense granule
release also depends on Ca2-sensitive MLC kinase activa-
tion (25). Inhibiting this kinase with ML-7 abolished both the
ATP release and platelet aggregation induced by collagen (2
g/ml) (Fig. 2B). As shown in Fig. 2A, ML-7 reduced the
shear-induced ATP release and platelet aggregation by about
30%, indicating a role for MLC kinase in SIPA and associated
platelet degranulation.
Secreted ADP and ATP in VWF-dependent Shear-induced
Platelet Release and Aggregation—Under stirring conditions in
an aggregometer, MLC kinase is activated downstream of the
P2X1-mediated Ca
2 influx, playing an essential role during cy-
toskeletal rearrangements evoked by selective agonists (,-
meATP and L-,-meATP) of this ion channel (25). The activation
of MLC kinase can also result from phospholipase C-dependent
Ca2 mobilization from internal stores downstream of the Gq
protein-coupled P2Y1 receptor or of GPVI (34, 35). In agreement
with earlier reports (17–19), the selective antagonists of P2Y1
(MRS2179, 10 M) and P2Y12 (AR-C69931MX, 1 M) inhibited
SIPA by more than 50% (Fig. 3). In previous studies of platelet
aggregation performed under stirring conditions in an aggre-
FIG. 1. Role of VWF and Ca2 in
shear-induced platelet aggregation
and ATP release. A, time course of
washed human platelet aggregation and
ATP release induced at a shear rate of
9000 s1 (black squares). The absence of
platelet responses at a shear rate of 1000
s1 is also shown (lower lines with open
squares). B, effects of preincubation with
the neutralizing anti-VWF monoclonal
antibody AJvW-2 (20 g/ml, 1 min), the
neutralizing anti-GPIb antibody G19H10
(20 g/ml, 1 min), or the IIb3 antagonist
tirofiban (1 g/ml, 1 min), as well as the
absence of added extracellular Ca2 on
aggregation induced for 3 min at 9000
s1. *, p  0.0001; #, p  0.0001 versus
control; §, p  0.0002.
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gometer, a high concentration of the ATP/ADP scavenger apyrase
always was required to demonstrate P2X1 function, as this ion
channel is rapidly desensitized by ATP released during platelet
preparation (23–25). In sharp contrast, the P2X1 antagonist
MRS2159 (10 M) reduced SIPA by about 40% even when
apyrase was omitted (Fig. 3). Thus, the three platelet P2 recep-
tors contribute to SIPA through secreted ADP and ATP. The
effect of combined P2X1 and P2Y1 antagonism on SIPA was not
significantly different from that of P2Y1 antagonism only (Fig. 3),
suggesting that these receptors share common signaling path-
ways. Neither the antagonism of P2X1, P2Y1, nor their combina-
tion could inhibit the remaining SIPA observed in the presence of
the P2Y12 antagonist (data not shown).
ATP secretion assays performed in the presence of the selec-
tive P2 receptor antagonists revealed a contribution of P2Y1,
P2Y12, and P2X1 to VWF-dependent platelet degranulation
(measured after 3 min) (Fig. 3). With the exception of P2X1
antagonism, the effects of P2Y1 and P2Y12 antagonism on se-
cretion did not fully correlate with their ability to inhibit plate-
let aggregation (Fig. 3), which is in agreement with the inter-
pretation that these receptors participate in other processes
leading to SIPA besides secretion regulation.
P2X1 Enhances Degranulation and SIPA via Calmodulin-de-
pendent MLC Kinase Activation—To further examine the con-
tribution of individual nucleotides to SIPA, we have used plate-
lets of a Hermansky-Pudlak patient lacking dense granules
and secreting almost no ATP in response to supraoptimal doses
of collagen (36). These platelets displayed severely impaired
SIPA comparable with SIPA observed in the presence of P2Y1
or P2Y12 receptor antagonists (Fig. 4A). Interestingly, platelet
aggregation could be largely restored by the addition of not only
ADP but also of the selective P2X1 agonist L-,-meATP imme-
diately prior to shearing, which supports the central roles for
both ATP and ADP secreted during SIPA.
We pursued this aspect of SIPA using normal platelets but in
the presence of the ectonucleotidase apyrase, which degrades
secreted ATP and ADP. The addition of apyrase (0.5 units/ml)
to the platelet resuspension buffer reduced the level of SIPA to
70% of the control (Fig. 4B). In this condition, the selective
P2Y1 and P2X1 receptor antagonists MRS2179 and MRS2159
no longer inhibited the remaining SIPA (not shown), indicating
that the reduction of aggregation by apyrase is due to the
absent activation of P2Y1 and P2X1 signaling (Fig. 4A). In
contrast, the P2Y12 antagonist still reduced the aggregation of
apyrase-treated platelets from 26.3  9.5% to 17.1  3.2%, in-
dicating the presence of sufficient remaining secreted ADP to
activate this receptor.
The addition of the selective apyrase-resistant P2X1 agonist
L-,-meATP to this set-up just prior to shearing fully restored
the aggregation of apyrase-treated platelets (Fig. 4B). The re-
sulting aggregation still depended on VWF and IIb3 activa-
tion, as shown by its full inhibition by AJvW-2 and tirofiban
(Fig. 4B). Therefore, this experimental approach enabled us to
study the P2X1-driven signaling pathways in more detail dur-
ing SIPA.
We found that the enhanced SIPA was the result of CaM and
MLC kinase activation, as W-7 and ML-7 inhibited the L-,-
FIG. 2. MLC kinase versus PKC in SIPA and platelet ATP re-
lease. A, aggregation of washed human platelets was induced for 3 min
at a shear rate of 9000 s1 following preincubation with the protein
kinase C inhibitors GF109203X (GF, 10 M, 5 min), Go6976 (1 M, 5
min), or Go6983 (1 M, 5 min) or the MLC kinase antagonist ML-7 (10
M, 10 min). The effect of these inhibitors on ATP secretion measured
after 3 min of shearing is also shown. *, p  0.05. B, aggregation of
washed human platelets produced in an aggregometer by collagen (2
g/ml) or TRAP1–6 (1 M SFFLRN) in the absence (control) or presence
() of the same inhibitors, as indicated. The corresponding concentra-
tions (M) of released ATP are shown in brackets.
FIG. 3. P2X1, P2Y1, and P2Y12 in SIPA and ATP release. A,
aggregation of washed platelets was induced for 3 min at a shear rate
of 9000 s1 following a 1-min preincubation with the selective P2
receptor antagonists for P2Y12 (AR-C69931MX, 1 M), P2Y1 (MRS2179,
10 M), and P2X1 (MRS2159, 10 M) or with combined MRS2179 
MRS2159. *, p  0.001; #, p  0.04 versus control. B, ATP secretion
measured after 3 min of shearing in the presence or absence of the P2
receptor antagonists. *, p  0.05; NS, not significant.
P2X1 Signaling in SIPA 26269
 at UNIV DE LIEG
E-M
M
E F PASLE on Septem









meATP amplification (Fig. 4B). Notably, these inhibitors had
no effect on the SIPA of apyrase-treated platelets without ad-
ditional stimulation by L-,-meATP (data not shown), indicat-
ing that the activation of these pathways exclusively depends
on P2X1 potentiation. The fact that W-7 inhibited the L-,-
meATP-driven SIPA to a larger extent than ML-7 may indicate
the existence of an additional CaM-dependent pathway acti-
vated downstream of P2X1. Thus, exogenous P2X1 activation
selectively triggers CaM-dependent pathways contributing to
SIPA. Moreover, in the presence of the P2Y12 receptor antag-
onist AR-C69931MX, the L-,-meATP-driven SIPA was re-
duced to the same level (16.2  3.4%) as that achieved during
inhibition of apyrase-treated platelets themselves, confirming
a central role for ADP also in the L-,-meATP-driven SIPA.
P2X1 Activation Promotes Shear-induced Platelet Granule
Centralization and Release—We investigated whether P2X1-
mediated MLC kinase activation would be instrumental in
platelet degranulation to explain the enhanced SIPA of Her-
mansky-Pudlak patient platelets or of apyrase-treated plate-
lets in the presence of L-,-meATP. Flow cytometry analysis of
P-selectin expression (as a marker of -granule release) was
done on the surface of apyrase-treated (0.5 units/ml) and tiro-
fiban-treated platelets exposed to VWF and shear for 5 min in
the presence or absence of L-,-meATP. Fig. 5 shows a signif-
icant increase of the percentage of platelets expressing P-selec-
tin following their pretreatment with L-,-meATP. P-selectin
expression was, in turn, reduced to the initial level in the
presence of the MLC kinase inhibitor ML-7 (Fig. 5). Therefore,
during SIPA, the P2X1-mediated MLC kinase activation can
reinforce the shear-induced platelet degranulation.
The ability of P2X1 to potentiate platelet aggregation during
SIPA was further investigated by electron microscopy of plate-
let aggregates (Fig. 5). Following 3 min of shearing, the apyrase
(0.5 units/ml)-treated platelets formed small aggregates and
displayed granule centralization and pseudopodia, but most of
the granules were intact (Fig. 5c). On the contrary, in the
presence of L-,-meATP, larger platelet aggregates were ob-
served in which more platelets were degranulated; in the plate-
lets still showing intact granules, their centralization appeared
more advanced than in the absence of L-,-meATP, indicative
of more pronounced cytoskeletal rearrangements (Fig. 5d).
Platelets subject to low shear stress (1000 s1 shear rate) did
not show any morphological changes (Fig. 5b) as compared with
resting platelets (Fig. 5a). Thus, P2X1-driven MLC kinase ac-
tivation in SIPA contributes both to cytoskeletal rearrange-
ments in platelets and to degranulation.
Shear-induced MLC Phosphorylation Depends on P2X1,
P2Y1, and P2Y12—Activation of CaM-regulated MLC kinase
and Rho kinase results in Ca2-dependent and -independent
phosphorylation of MLC (34), which is a key step in platelet
activation. Shear stress caused phosphorylation of MLC (de-
tected as early as 20 s and reaching its maximum after 3 min)
(Fig. 6A), which was inhibited both by ML-7 and the Rho kinase
inhibitor Y-27632 (Fig. 6B). Such phosphorylation was not af-
fected by the IIb3 antagonist tirofiban (Fig. 6B), indicating
that it occurred independently of IIb3 outside-in signals. In
agreement with a role for Rho kinase in SIPA, platelet aggre-
gation was reduced from 43.9  9.5% to 23.6  8.7% by adding
Y-27632 (5 M) during SIPA (37).
We found that antagonizing P2X1 (MRS2159), P2Y1
FIG. 4. P2X1 activation potentiates
SIPA through CaM and MLC kinase.
A, SIPA with platelets from a Herman-
sky-Pudlak patient (HPS) compared with
platelets from healthy individuals (con-
trol). L-,-meATP (10 M) or ADP (1 M)
was added to the Hermansky-Pudlak pa-
tient platelets prior to shearing, as indi-
cated. B, aggregation of washed platelets
and of apyrase (0.5 units/ml)-treated
platelets was induced for 3 min at a shear
rate of 9000 s1 (control) in the presence
or in the absence of the selective P2X1
agonist L-,-meATP (10 M) following
preincubation with the neutralizing anti-
VWF monoclonal antibody AJvW-2 (20
g/ml), the IIb3 antagonist tirofiban
(tir, 1 g/ml), the CaM antagonist W-7
(100 M), the MLC kinase antagonist
ML-7 (10 M), or the P2Y12 antagonist
AR-C69931MX, as indicated. $, p  0.004
versus control; *, p  0.001 versus
apyrase  L-,-meATP; **, p  0.005; #,
p  0.01 versus apyrase  L-,-meATP;
¶, p  0.02 versus presence of W-7). The
presence of apyrase and L-,-meATP are
represented by solid black lines under-
scoring the graph.
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(MRS2179), or P2Y12 (AR-C69931MX) inhibited phosphoryla-
tion of MLC to a variable degree (Fig. 6B). Phosphorylation was
inhibited potently by P2X1 neutralization. Correspondingly,
the addition of 0.5 units/ml apyrase (i.e. abolishing platelet
activation via P2Y1 and P2X1) almost abolished MLC phospho-
rylation (Fig. 6C); moreover, shearing for 20 s resulted in a
phosphorylation state below that of resting platelets (Fig. 6C).
The addition of 5 units/ml apyrase abrogated the overall re-
sponse (Fig. 6D), which could not be restored by doubling the
concentration of exogenous VWF (20 g/ml) (Fig. 6D), even
though this led to an 20% increase of aggregation (not
shown). Thus, VWF does not trigger MLC phosphorylation
without involving secreted nucleotides.
Fig. 6C also shows that, in the presence of 0.5 units/ml
apyrase, the addition of L-,-meATP prior to shear potently
enhanced MLC phosphorylation induced after 20 and 60 s; such
L-,-meATP-elicited phosphorylation was quickly reversible
as it was no longer detected after 3 min. Therefore, the ability
of L-,-meATP to cause MLC phosphorylation coincides with
its ability to potentiate the shear-induced aggregation of
apyrase-treated platelets.
DISCUSSION
In the present study, we describe a role for the P2X1-medi-
ated CaM and MLC kinase activation in VWF-dependent SIPA
through secreted ATP. This pathway contributes to the extra-
cellular Ca2-dependent platelet degranulation induced by
shear stress and acts in conjunction with VWF-GPIb signal-
ing. As schematically represented in Fig. 7, platelet activation
initiated by the VWF-GPIb interaction required a transmem-
brane Ca2 influx independent of both ADP and VWF binding
to IIb3 (14, 15). Our observation that the P2X1 receptor an-
tagonist MRS2159 only partly inhibits platelet degranulation
and aggregation (to a maximum of 60%), whereas omitting
extracellular Ca2 or neutralizing VWF abolishes it, suggests
that the VWF/GPIb-associated transmembrane Ca2 influx
only partly relies on P2X1-mediated Ca
2 influx.
In contrast to the effects on aggregation, the removal of VWF
or antagonizing its binding to GPIb only partially reduced the
shear-induced platelet ATP release unless extracellular Ca2
was omitted at the same time. The antagonist of IIb3, tirofi-
ban, had no effect on shear-induced platelet release, excluding
contributions by VWF-IIb3 outside-in signaling to secretion
regulation. Antagonizing P2X1 with MRS2159 diminished the
ATP release, which was also seen with the antagonism of P2Y1
and P2Y12, indicating a role for all of these receptors in the
amplification of the VWF/GPIb-triggered platelet degranula-
tion (Fig. 7).
The ATP-gated P2X1 ion channel only operates in the presence
of physiological extracellular Ca2 concentrations (23, 24). Ca2
is a key element in granule secretion (reviewed in Ref. 31). The
proteins that mediate the effects of Ca2 in secretion fall into two
categories: the EF hand proteins and the Ca2/phospholipid-
binding proteins. EF hand proteins found in platelets include
calmodulin and calcyclin. Calmodulin binds to platelet -gran-
ules. Ca2/calmodulin-dependent phosphorylation of MLC ki-
FIG. 5. P2X1 activation enhances platelet degranulation. Upper
panel, flow cytometry analyses of P-selectin surface expression on tiro-
fiban- and apyrase (0.5 units/ml)-treated washed platelets exposed to
VWF at a shear rate of 9000 s1 for 5 min or not (control) in the presence
or absence of L-,-meATP (10 M) and the MLC kinase inhibitor ML-7
(10 M) as indicated. #, p  0.01 versus control; *, p  0.02 versus
absence of L-,-meATP; **, p  0.04 versus presence of L-,-meATP.
Lower panels (a–d), transmission electron microscopy of SIPA. Apyrase
(0.5 unit/ml)-treated washed human platelets were subjected or not (a)
to a shear rate of 1000 s1 (b) or 9000 s1 (c) in the absence or presence
of L-,-meATP (10 M) (d) for 3 min before being analyzed by electron
microscopy. Scale bars  1 m.
FIG. 6. Shear-induced MLC phosphorylation depends exclu-
sively on secreted ATP and ADP. A, Western blotting of MLC
phosphorylation (P-MLC) at a shear rate of 9000 s1. The time course of
MLC phosphorylation in the absence of apyrase is shown. B, MLC-
phosphorylation produced after 3 min of shear following preincubation
with the selective P2 receptor antagonists (as described in the legend
for Fig. 3), ML-7 (in Fig. 2), Y-27632 (5 M), or tirofiban (in Fig. 1B), as
indicated. C, same experiment as in A performed on platelets treated
with 0.5 units/ml apyrase in the absence or presence of L-,-meATP (10
M). D, platelets were treated with 5 units/ml apyrase, and shear was
applied for 3 min in the presence of 10 or 20 g/ml VWF, as indicated.
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nase mediates secretion via activation of MLC with subsequent
contraction of the actomyosin; therefore, the concurrent central-
ization of granules is thought to facilitate granule secretion (38).
Calmodulin may also bind specifically to the vesicle-associated
membrane protein (39), contributing to granule release by di-
rectly affecting the exocytotic core complex.
Here, we found that shear-induced MLC phosphorylation
involves both Ca2-dependent MLC kinase and Ca2-inde-
pendent Rho kinase signaling, as it was inhibited by the MLC
kinase inhibitor ML-7 as well as by the Rho kinase inhibitor
Y-27632. The phosphorylation of MLC was abolished by the
ATP/ADP scavenger apyrase and was potently reduced by the
selective antagonism of P2X1, P2Y1, or P2Y12, indicating a
central role for secreted ATP and ADP in this event.
Compatible with a prominent role for the P2X1 ion channel
under high shear stress (26, 27), apyrase was not needed to
demonstrate P2X1 function during SIPA. On the other hand,
apyrase could be used under these conditions to control P2X1
function via the addition of stable selective P2X1 agonists and
to drive platelet activation through P2X1-dependent pathways
of signaling. The ability of the selective P2X1 agonist L-,-
meATP to restore the aggregation of apyrase-treated platelets
coincided with its potency in causing early phosphorylation of
MLC and increased platelet P-selectin expression, a marker of
-granule release. The potentiating effect of L-,-meATP on
SIPA was prevented by inhibitors of CaM (W-7) and of MLC
kinase (ML-7). These findings were substantiated by electron
microscopy analyses of the platelet aggregates, depicting more
pronounced granule centralization as well as degranulation in
the presence of L-,-meATP. Our observation that exogenous
P2X1 activation can restore the severely defective SIPA of
platelets lacking dense granules (Hermansky-Pudlak patient)
corroborates a role for P2X1-mediated cytoskeletal rearrange-
ments in facilitating -granule release.
Thus, our findings suggest that P2X1 participates in the
extracellular Ca2-dependent shear-induced platelet granule
release through CaM and MLC kinase-triggered MLC phospho-
rylation and concurrent cytoskeletal rearrangements, facilitat-
ing SIPA and leading to granule centralization as an onset to
degranulation (Fig. 7). Because P2Y1 antagonism also inhibited
shear-induced MLC phosphorylation (although weakly), a role
for Ca2 mobilized from internal stores in MLC kinase activa-
tion is possible (34, 35). Rapid P2X1 and slower P2Y1 signals
(activated by co-released ATP and ADP, respectively) converge
to a common effector (MLC kinase) contributing to cytoskeleton
remodeling and platelet release (Fig. 7). Accordingly, combined
P2X1 and P2Y1 antagonism leads to the same inhibition of
SIPA at 3 min as P2Y1 antagonism only.
The study by Schoenwaelder et al. (37) defines an important
role for RhoA and Rho kinase in SIPA but not in platelet
release. The inhibition of shear-induced MLC phosphorylation
by selective P2Y1 or P2Y12 antagonism suggests that ADP
activates Rho kinase through Gq (40) and Gi2 (41) also under
shear stress (Fig. 7). Further investigations are required to
determine the function of these pathways during SIPA. The
failure of Rho kinase inhibitors to affect platelet release (Ref.
37 and the present study) may be explained by the existence of
two pools of myosin present in different cell compartments (42)
and emphasizes the role of MLC kinase activation in nucleo-
tide-mediated granule release. In agreement with findings by
Rese´ndez et al. (19), we further found that P2Y12 mediated
PI3K activation during SIPA. The resulting Akt (protein kinase
B) phosphorylation was inhibited by P2Y12 neutralization.
PI3K inhibition partially inhibited SIPA but had no effect on
ATP release (not shown); i.e. P2Y12-recruited PI3K activates
platelets via a separate pathway (Fig. 7) potentially by regu-
lating the function of IIb3 via Akt and the integrin-linked
kinase ILK (43).
Platelet granule release induced by most platelet agonists
depends on PKC activation (reviewed in Ref. 31). However,
none of the PKC inhibitors used in this study affected the
shear-induced platelet release or aggregation. The nonselective
PKC inhibitor GF109203X (which blocks both diacylglycerol-
and Ca2-sensitive conventional PKC isoforms and the diacyl-
glycerol-sensitive Ca2-insensitive novel isoforms), the more
potent PKC /-specific inhibitor Go6976, and Go6983 (which
inhibits the atypical 	 isoform in addition to , , , and ) were
all without effect, even though they inhibited platelet release in
response to collagen or TRAP1–6. This finding is consistent
with a previous study in which the nonselective protein kinase
inhibitor staurosporine failed to inhibit SIPA (32). This is in
contrast to the study by Kroll et al. (8) showing inhibition of the
full aggregation response by the staurosporine analogue Ro
31-7549. The effect of this inhibitor on platelet release was not
reported in their study. Ro 31-7549, similar to Ro 31-8220 and
GF109203X, belongs to a category of nonselective PKC inhibi-
tors showing similar potency in inhibiting collagen-, thrombox-
ane A2 analogue-, and thrombin-induced platelet release and
aggregation (29, 33, 44). These authors show that SIPA is
associated with the phosphorylation of pleckstrin, a PKC sub-
strate that occurs in the absence of diacylglycerol or hydrolysis
of phosphatidylinositol 4,5-bisphosphate in a Ca2-dependent
manner. It has to be noticed that EGTA, a chelator of extracel-
lular Ca2, had minimal effect on such phosphorylation, ex-
cluding a role for transmembrane Ca2 influx. They conclude
that a diacylglycerol-independent pathway of PKC activation
FIG. 7. Schematic representation of the central role of P2 re-
ceptor signaling in SIPA. In addition to the shear-induced interac-
tion of VWF with GPIb, a role for all three P2 receptors is depicted in
SIPA. Extracellular Ca2-dependent GPIb signaling triggers cytoskel-
etal rearrangements and IIb3 activation but also early degranulation
leading to subsequent activation of P2 receptors via released ADP and
ATP. Downstream P2 receptor pathways include P2Y1-mediated Ca
2
mobilization and P2X1-mediated Ca
2 influx, as well as P2Y12-depend-
ent PI3K and Akt activation and RhoA/Rho kinase activation. The three
P2 receptors are needed to cause MLC phosphorylation through CaM/
MLC kinase and/or RhoA/Rho kinase pathways, leading to shear-asso-
ciated cytoskeletal reorganization, facilitating platelet aggregation and
enhancing platelet secretion. The fast ATP-activated Ca2 influx
through P2X1 triggers rapid CaM activation, which is critical for a
process requiring a prompt platelet-activating signal. eCa2 and iCa2,
extracellular and intracellular Ca2, respectively.
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contributes to SIPA. Thus, although involvement of an un-
known PKC isoform in shear-induced platelet granule release
cannot be ruled out, our data clearly distinguished this process
from the GPVI- and PAR-1-mediated granule release (33). Fi-
nally, the study by Nakai et al. (21) describes the shear-induced
cytoskeleton translocation of actin, actin-binding protein, and
myosin as a rapid and transient movement of MLC kinase
wherein the amount of cytoskeletal PKC did not change, unlike
what is seen with thrombin. This observation further suggests
distinct roles of PKC (if any) and MLC kinase during platelet
responses to shear stress. The transient association of MLC
kinase with the cytoskeleton may coincide with the quickly
reversible MLC phosphorylation produced via P2X1 activation.
In conclusion, P2X1 contributes to SIPA through its ability to
rapidly elicit Ca2 influx-triggered signals leading to prompt
CaM-dependent signaling, platelet activation, and platelet
granule release. Further studies are required to elucidate the
mechanisms of VWF-GPIb-dependent platelet granule re-
lease. It also remains to be determined whether the presently
identified P2X1/CaM/MLC kinase pathway plays a role during
platelet activation processes accompanying platelet recruit-
ment and adhesion on immobilized VWF and, most impor-
tantly, during thrombosis.
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